BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sapacitabine: SPA received

Cyclacel received an SPA from FDA for a planned Phase III trial to compare oral sapacitabine vs. an active control in newly diagnosed AML patients aged 70 years or...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >